From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis
Nucleic Acid Therapeutics · 2023
DOI: 10.1089/nat.2023.0027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2023. Verfasst von Willeke van Roon-Mom und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Dutch Center for RNA Therapeutics, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Oligonucleotides, Antisense. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Dutch Center for RNA Therapeutics, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
- RNA Therapeutics Institute, UMass Chan Medical School, Worcester, Massachusetts, USA.
ORCID-Profile: Willeke van Roon-Mom, Annemieke Aartsma-Rus
Zitieren
APA
van Roon-Mom, W., Ferguson, C., & Aartsma-Rus, A. (2023). From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2023.0027
Vancouver
van Roon-Mom W, Ferguson C, Aartsma-Rus A. From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis. Nucleic Acid Therapeutics. 2023. doi:10.1089/nat.2023.0027
BibTeX
@article{vanRoonMom2023,
author = {van Roon-Mom, Willeke and Ferguson, Chantal and Aartsma-Rus, Annemieke},
title = {From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis},
journal = {Nucleic Acid Therapeutics},
year = {2023},
doi = {10.1089/nat.2023.0027}
}
EUVIMED